| Literature DB >> 31790297 |
Sarah MacIsaac1,2, Iqbal H Jaffer2,3, Emilie P Belley-Côté2,4,5, Graham R McClure2,6,7,4, John W Eikelboom2,3,5, Richard P Whitlock2,4.
Abstract
Managing severe valvular heart disease with mechanical valve replacement necessitates lifelong anticoagulation with a vitamin K antagonist. Optimal anticoagulation intensity for patients with mechanical valves remains uncertain; current recommendations are inconsistent across guideline bodies and largely based on expert opinion. In this review, we outline the history of anticoagulation therapy in patients with mechanical heart valves and critically evaluate current antithrombotic guidelines for these patients. We conclude that randomized trials evaluating optimal anticoagulation intensity in patients with mechanical valves are needed, and that future guidelines must better justify antithrombotic treatment recommendations.Entities:
Keywords: anticoagulation agents; best practices; cardiac valve prosthesis; vitamin K
Year: 2019 PMID: 31790297 DOI: 10.1161/CIRCULATIONAHA.119.041105
Source DB: PubMed Journal: Circulation ISSN: 0009-7322 Impact factor: 29.690